Related references
Note: Only part of the references are listed.Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models
Elisa Baldelli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors
Yan Liu et al.
LUNG CANCER (2021)
Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
Ferdinandos Skoulidis et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy
Adileh Ayati et al.
BIOORGANIC CHEMISTRY (2020)
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
P.A. Jänne et al.
EUROPEAN JOURNAL OF CANCER (2020)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Chiara Ambrogio et al.
CELL (2018)
Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Jens Kohler et al.
CURRENT MEDICINAL CHEMISTRY (2018)
Regulation of the master regulator FOXM1 in cancer
Guo-Bin Liao et al.
CELL COMMUNICATION AND SIGNALING (2018)
Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
Jialing Zhang et al.
PRECISION CLINICAL MEDICINE (2018)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Roles of FoxM1 in cell regulation and breast cancer targeting therapy
Xin Song et al.
MEDICAL ONCOLOGY (2017)
KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers
Gary J. Doherty et al.
TRENDS IN MOLECULAR MEDICINE (2017)
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
J. -C. Soria et al.
ANNALS OF ONCOLOGY (2017)
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers
Maria Isabella Sereni et al.
BRITISH JOURNAL OF CANCER (2017)
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer
Michael R. Burgess et al.
CELL (2017)
Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer A Review
Kevin Wood et al.
JAMA ONCOLOGY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
The Soft Agar Colony Formation Assay
Stanley Borowicz et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
FOXM1: From cancer initiation to progression and treatment
Chuay-Yeng Koo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2012)
A Comprehensive Survey of Ras Mutations in Cancer
Ian A. Prior et al.
CANCER RESEARCH (2012)
Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance
Fung Zhao et al.
Frontiers of Medicine (2012)
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
Vienna Ludovini et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Clinical Relevance of KRAS in Human Cancers
Sylwia Jancik et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2010)
The Forkhead Box M1 transcription factor contributes to the development and growth of mouse colorectal cancer
Yuichi Yoshida et al.
GASTROENTEROLOGY (2007)
Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1
Senthil K. Radhakrishnan et al.
CANCER RESEARCH (2006)
The forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer
IM Kim et al.
CANCER RESEARCH (2006)
Development of farnesyl transferase inhibitors: A review
NMGM Appels et al.
ONCOLOGIST (2005)
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer
M Crul et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
J Zujewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
